Commentary on Phosphodiesterase 5 Inhibitor Mirodenafil Ameliorates Alzheimer-Like Pathology and Symptoms by Multimodal Actions
David R. Greeley, MD, FAAN
Chief Medical Officer, AriBio LLC
Clinical Associate Professor University of Washington School of Medicine, Dept of Neurology
Fellow American Academy of Neurology
Board-certified Neurologist, Northwest Neurological, PLLC
Principal Investigator, Kingfisher Cooperative, LLC
Greeley DR (2022) Commentary on Phosphodiesterase 5 Inhibitor Mirodenafil Ameliorates Alzheimer-Like Pathology and Symptoms by Multimodal Actions. Appl Cell Biol, 10(3), 2022 [113-113]